drugset / Trial / NCT05481151

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

NCT05481151

Phase 3 Active not recruiting 111 enrolled PharmaEssentia
RandomizedParallel-groupOpen-labelTreatment

Summary

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Timeline

Start
2022-10-26
Primary completion
2025-06-30
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropeginterferon alfa-2b Protein / enzyme biologic 500 ug Subcutaneous